Business Wire

AGERAS

Share
Ageras Launches Small-Biz Inflation Tracker, Finds Inflation Rates Outpacing Prices Charged by Europe’s Smallest Businesses

Ageras, the leading fintech company utilizing its banking and accounting software to power more than one million small businesses across Europe and the United States, announced today that it launched its proprietary Inflation Tracker, revealing how the rise in the Consumer Price Index dramatically outpaced the rise in prices billed by Europe’s small businesses across seven Western European economies in the most recent quarter.

By comparing how much tens of thousands of freelancers, microbusinesses, and other SMEs raised the prices for the same set of goods via Ageras’ accounting software between July through September versus the rise in each country’s official Consumer Price Index, Ageras data provides insight into how the smallest business owners across some of Europe’s largest economies are faring relative to overall inflation rates.

“We launched our index because we wanted to objectively study and highlight the unique challenges facing the economy's unsung heroes — sole proprietors and other small businesses,” said Ageras Co-founder Martin Hegelund. “Our data in this inaugural report show that inflation left small business owners worse off in every country we studied. We hope these data are a wake-up call for policymakers to focus more on inflation’s outsized impact on small businesses.”

Ageras’ index focused on seven European economies--Austria, Belgium, Denmark, France, Germany, Switzerland, and the United Kingdom. It chose these countries because Ageras’ software suite is most heavily used there, and its dataset is strongest. Ageras’ future index reports will expand the countries it studies.

In Europe’s largest economies, the CPI rose between 2% to 3% faster than price hikes by small businesses. In France and Germany, there was a 2.6% gap between official CPI data and SMEs studied by Ageras. In the United Kingdom, inflation’s impact was slightly weaker. Prices there rose 2.2% faster than SMEs raised their prices.

However, inflation’s largest impact was across some of Western Europe’s small countries in the most recent quarter.

Among the seven countries that Ageras’ index measured, inflation’s impact hit SMEs in Austria hardest. Austria’s CPI rose 5.3% faster than small businesses raised their prices last quarter. The gap was second highest in Belgium at 4.4%, followed by Denmark at 4.2%. Small business owners were best off in Switzerland, where the CPI rose 0.8% faster than SMEs raised the price of their goods.

Here are the full country reports (alphabetically ordered) using Ageras’ proprietary dataset:

Austria:
Ageras data show small business owners in Austria raised their prices by 4.5% in Q3 of 2022 compared to the third quarter of 2021. That lagged behind the 9.8% rise in Austria’s CPI during the same time period.

Belgium:
Ageras data show small business owners in Belgium raised their prices by 5.9% in the third quarter compared to the last year. That was dwarfed by the 10.3% rise in Belgium’s CPI during the same period.

Denmark:
Ageras data show small business owners in Denmark raised their prices by 5% in Q3. That rate trailed the 9.2% rise in Denmark’s latest CPI.

France:
Ageras data show small business owners in France raised their prices by 3.2% in Q3. That was lower than the 5.8% rise in France’s Q3 CPI.

Germany:
Ageras data show small business owners in Germany raised their prices by 5.9% in Q3 2022 compared to last year. That rate was below the 8.5% rise in Germany’s Q3 CPI.

Switzerland:
Ageras data show small business owners in Switzerland raised their prices by 2.6% in Q3. During that same time period, Switzerland’s CPI rose at a higher rate, 3.4%.

United Kingdom:
Ageras data show small business owners in the United Kingdom raised their prices by 6.5% in Q3 2022. That rate was less than the 8.7% rise in the UK’s CPI last quarter.

About Ageras:

Ageras is the ultimate fintech platform for small business owners. Its one-stop platform integrates its solutions into a single “financial cockpit” for invoicing, accounting, payroll, and banking, enabling small business owners and entrepreneurs to focus on what they do best: running their businesses. Ageras began as the online marketplace Ageras.com (matching SMEs with accountants) and has expanded into a 350-person company offering a complete ecosystem of tools and services for SMEs. Today, Ageras offers cloud-based accounting software through its products Zervant, Billy, and Tellow, banking through Kontist, and payroll software through Salary. In late 2021, the group launched an embedded fintech service that directly provides financing options to its customers through its software. Ageras’ solutions have been used by more than one million small businesses across Europe and the U.S. The company was founded in 2012 by serial entrepreneurs Rico Andersen and Martin Hegelund, who have 25 years of combined experience building internet companies. For more information, please visit www.ageras.group.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005038/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye